Ovarian cancer mortality rates declined significantly in several parts of the world from 2002 to 2012, according to a new study. Among the main reasons for the decline is the use of oral contraceptives, particular in the United States and European Union.
The use of telephone counseling for hereditary breast and ovarian cancer was noninferior to in-person counseling with no significant adverse effects on long-term outcomes.
Over a 10-year period, the use of neoadjuvant chemotherapy increased significantly in women with advanced ovarian cancer, according to a new observational study.
HIV infection significantly decreases survival among women with invasive cervical cancer, according to a study conducted in Botswana. This was the case even though most women with HIV received antiretroviral therapy.
The use of electric power morcellation for hysterectomy has declined since the FDA warned that the procedure, which fragments the uterus into smaller pieces, may result in the spread of undetected malignancies.
In a new practice guideline, the American Society of Clinical Oncology offered recommendations on the use of neoadjuvant chemotherapy and interval cytoreduction for women with stage IIIC or IV epithelial ovarian cancer.
A study found that follicle-stimulating hormone receptors are expressed in many ovarian tumors, and not in normal ovarian tissue, thus representing a promising therapeutic target.
In this interview we discuss a joint statement from MD Anderson and 68 other NCI-designated cancer centers that calls for increased HPV vaccination for the prevention of cancer.
Low-grade serous ovarian cancer is a rare, slow-growing cancer that is generally resistant to cytotoxic chemotherapy. In the upfront setting, treatment recommendations mimic those of high-grade serous ovarian cancer.
Elevated levels of neopterin were found to be significantly associated with poorer survival outcomes in patients with ovarian cancer.